Igf Oncology, LLC

Other

Square, Inc.

University of Minnesota

Novus Energy LLC

University of Arkansas

Bioventures, LLC

Squarox, LLC

Strokemaster Backboard, LLC

Squarex Pharmaceutical Corporation

Hugh McTavish

John D Offerman

Delman R Hogen

Thomas Dag Horn

Jeffrey W Lighthart

Sandra Marchese Johnson

Johannes N Gaston

Douglas J VanOrnum

Brian D Gale

Steven A Beaudry

Arkadiusz Z Dudek

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site other than at the site of an HSV lesion to induce a DTH response during one or more outbreaks of the HSV infection. The method reduces the number of HSV outbreaks in persons experiencing outbreaks.

Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection

A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti-viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.

Topical immunosensitizers to treat viral and fungal infections

Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.

Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome

Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.

Compounds and methods for treating cancer

The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer.

Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer

The invention provides a new tennis backboard design. The backboard includes a firm backing layer underlying a soft deadening layer. The rebound of a tennis ball from the backboard is reduced as compared to rebound from a rigid hard-surface backboard. This allows a player to stand fairly close to the backboard, which reduces misses. The player can stand fairly close and hit balls hard against the backboard. Because the rebound is reduced, the ball simply bounces back softly and easily to the player, allowing the player to hit hard again from a fairly short distance. Thus, long rallies without missing are easily achieved. Since the bounce is reduced, the player can stand closer to the backboard, and therefore the backboard can be smaller than conventional backboards without the player missing the backboard. This allows the backboard to be light, portable, and easily stored. Because of the addition of a soft deadening layer, the firm backing layer of the backboard can also be thin and made of lighter and weaker material than a conventional backboard, reducing the weight of the backboard.

Growing community of inventors

Birchwood, MN, United States of America

Hugh McTavish